Abstract
A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have